Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Published:2014-05 Issue:5 Volume:2 Page:369-384
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Barnett Anthony H,Mithal Ambrish,Manassie Jenny,Jones Russell,Rattunde Henning,Woerle Hans J,Broedl Uli C

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease;Kidney Int Suppl,2013

2. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment;Meyers;Postgrad Med,2011

3. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area;Coll-de-Tuero;BMC Nephrol,2012

4. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States;Koro;Clin Ther,2009

5. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization;Go;N Engl J Med,2004

Cited by 480 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits;Cellular Signalling;2024-10

2. Empagliflozin-A Sodium Glucose Co-transporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology;Current Diabetes Reviews;2024-10

3. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

4. A Trajetória das Gliflozinas: Da Casca da Macieira à Redução de Mortalidade Total na Insuficiência Cardíaca;ABC Heart Failure & Cardiomyopathy;2024-09-06

5. The Trajectory of Gliflozins: From Apple Tree Bark to Reduced Overall Mortality in Heart Failure;ABC Heart Fail Cardiomyop;2024-09